title: Multifactorial intervention in Type 2 diabetes: the promise of incretin-based therapies.
abstract: Type 2 diabetes mellitus is increasing in prevalence at alarming rates. Concurrent with its expanding prevalence is the increase in the related risk of morbidity and mortality. Because diabetic patients are prone to cardiovascular disease, treatment strategies should address the cardiovascular risk factors, including blood pressure, lipids, and body weight, in addition to the glycemic aspects of the disease. Newer agents, such as glucagon-like peptide-1 (GLP-1) analogs and dipeptidyl peptidase-4 (DPP-4) inhibitors, have varying degrees of evidence to support their effects on body weight, blood pressure, and lipid levels, beyond glycated hemoglobin reduction. While GLP-1 agonists produce a weight loss, the DPP-4 inhibitors, conversely, appear to have a weight-neutral effect. Substantial evidence demonstrates that both medications produce modest reductions in systolic blood pressure and, in some cases, diastolic blood pressure, and reduce several markers of cardiovascular risk, including C-reactive protein. Moreover, GLP-1 influences endothelial function. The effect of the incretin hormones on serum lipids are either neutral or beneficial, with small, non-significant decreases in LDL cholesterol, increases in HDL cholesterol, and occasionally significant decreases in fasting triglyceride levels. Also, they have positive effects on hepatic steatosis. Although GLP-1 agonists and DPP-4 inhibitors are at present not appropriate for primary treatment of cardiovascular risks factors, the reduction of these parameters is evidently beneficial.
authors.affiliation: Department of Emergency and Organ Transplantation, Section of Internal Medicine, Endocrinology, Andrology and Metabolic Diseases, University of Bari Aldo Moro, Piazza Giulio Cesare, 11, I- 70124 Bari, Italy. f.giorgino@endo.uniba.it
authors.forename: F
authors.initials: F
authors.lastname: Giorgino
authors.forename: A
authors.initials: A
authors.lastname: Leonardini
authors.forename: A
authors.initials: A
authors.lastname: Natalicchio
authors.forename: L
authors.initials: L
authors.lastname: Laviola
mesh_terms: D000818:Animals; D003131:Combined Modality Therapy / Q000379:methods* / Q000639:trends; D003924:Diabetes Mellitus, Type 2 / Q000097:blood / Q000150:complications / Q000628:therapy*; D052216:Glucagon-Like Peptide 1 / Q000494:pharmacology; D006301:Health Services Needs and Demand; D006801:Humans; D054795:Incretins / Q000502:physiology / Q000627:therapeutic use*; D008954:Models, Biological; D010347:Patient Care Planning / Q000639:trends
chemical_list: D054795:Incretins; D052216:Glucagon-Like Peptide 1